| Sign In to gain access to subscriptions and/or personal tools. |
Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitusSchool of Medicine and Pharmacology, University of Western Australia, PO Box X2213, Perth, Western Australia, 6847, Australia.
School of Medicine and Pharmacology, University of Western Australia, PO Box X2213, Perth, Western Australia, 6847, Australia.
School of Medicine and Pharmacology, University of Western Australia, PO Box X2213, Perth, Western Australia, 6847, Australia. Endothelial dysfunction is universal in diabetes, being intimately involved with the development of cardiovascular disease. The pathogenesis of endothelial dysfunction in diabetes is complex. It is initially related to the effects of fatty acids and insulin resistance on ‘uncoupling’ of both endothelial nitric oxide synthase activity and mitochondrial function. Oxidative stress activates protein kinase C (PKC), polyol, hexosamine and nuclear factor kappa B pathways, thereby aggravating endothelial dysfunction.
Improvements in endothelial function in the peripheral circulation in diabetes have been demonstrated with monotherapies, including statins, fibrates, angiotensin-converting enzyme (ACE) inhibitors, metformin and fish oils. These observations are supported by large clinical end point trials. Other studies show benefits with certain antioxidants, L-arginine, folate, PKC-inhibitors, peroxi-some proliferator activated receptor (PPAR)- Measurement of endothelial dysfunction in cardiovascular research can provide fresh opportunities for exploring the mechanism of benefit of new therapeutic regimens and for planning and designing large clinical trials.
Key Words: endothelial dysfunction • diabetes • statins • fibrates • antihypertensive agents • antioxidants • combination therapies • antiglycaemic agents
Diabetes and Vascular Disease Research, Vol. 4, No. 2,
89-102 (2007) This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
and -
agonists and phosphodiesterase (PDE-5) inhibitors. However, the benefits of these agents remain to be shown in clinical end point trials. Combination treatments, for example, statins plus ACE inhibitors and statins plus fibrates, have also been demonstrated to have additive benefits on endothelial function in diabetes, but there are no clinical outcome data to date. 
